Surgical infection society guidelines for vaccination after traumatic injury

Surgical Infections

Volumn 7, Issue 3, 2006, Pages 275-303

  Howdieshell, Thomas R ^a,c   Heffernan, Daithi ^a   Dipiro, Joseph T ^b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTHRAX VACCINE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; BAYTET; CIPROFLOXACIN; DECAVAC; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; DIPHTHERIA TOXOID; DIPLOID CELL VACCINE; DOXYCYCLINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; MENINGOCOCCUS VACCINE; PENICILLIN V POTASSIUM; PLACEBO; PNEUMOCOCCUS VACCINE; PNU IMMUNE 23; POLYSACCHARIDE VACCINE; RABIES IMMUNOGLOBULIN; RABIES VACCINE; STEROID; SULFONAMIDE; TETANUS ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTHRAX; ARTHRALGIA; ARTHRITIS; BACTERIAL STRAIN; BODY TEMPERATURE DISORDER; CHILL; CITATION ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; COCHRANE LIBRARY; DIPHTHERIA; DISEASE SEVERITY; DIZZINESS; DOSE CALCULATION; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG SAFETY; ELECTIVE SURGERY; EMERGENCY SURGERY; EVIDENCE BASED PRACTICE; FATIGUE; FEVER; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPOTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOTOXICITY; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; INFORMATION RETRIEVAL; INJECTION SITE DISCOMFORT; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJURY; INTERNET; IRRITABILITY; LETHARGY; MALAISE; MEDICAL EXPERT; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDLINE; MENINGOCOCCOSIS; MYALGIA; NAUSEA; NEPHROTIC SYNDROME; NEUROPATHY; NONHUMAN; PATHOGENESIS; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PUBLIC HEALTH SERVICE; PUBLICATION; RABIES; REVACCINATION; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SPLEEN FUNCTION; SPLEEN INJURY; SPLENECTOMY; STREPTOCOCCUS INFECTION; TETANUS; URTICARIA; VACCINE FAILURE; VIRUS STRAIN; WOUND INFECTION;

AGE FACTORS; ANTHRAX; ANTHRAX VACCINES; BIOTERRORISM; EVIDENCE-BASED MEDICINE; HUMANS; RABIES; RABIES VACCINES; SPLENECTOMY; TETANUS; TETANUS TOXOID; VACCINATION; VACCINES; WOUNDS AND INJURIES;

EID: 33746908168     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2006.7.275     Document Type: Review

References (158)

1. Plotkin SA. Vaccines in the 21st century. Infect Dis Clin North Am 2001;15:307-324.
2. Moran GJ, Talan DA, Mower W, et al. Appropriateness of rabies postexposure prophylaxis treatment for animal exposures. JAMA 2000;284:1001-1007.
3. Gergen PJ, McQuinllan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 1995;332:761-813.
4. Shatz DV. Vaccination practices among North American trauma surgeons in splenectomy for trauma. J Trauma 2002;53:950-956.
5. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989;95:25-45.
6. Noah DL. Epidemiology of human rabies in the United States, 1980 to 1986. Ann Intern Med 1998; 128:922-930.
7. Weiss HB, Friedman DI, Coben JH. Incidence of dog bite injuries treated in emergency departments. JAMA 1998;279:51-53.
8. Krebs JW, Smith JS, Rupprecht CE, et al. Rabies surveillance in the United States during 1997. J Am Vet Med Assoc 1998;213:1713-1728.
9. Centers for Disease Control and Prevention. Update: Raccoon rabies epizootic - United States, 1996. MMWR 1997;45:1117-1120.
10. Krebs JW, Long-Marin SC, Childs JE. Causes, costs, and estimates of rabies postexposure prophylaxis treatments in the United States. J Public Health Manage Pract 1998;4:56-62.
11. King AA, Meredith CD, Thomson GR. The biology of southern African lyssavirus variants. Curr Top Microbiol Immunol 1994;187:267-295.
12. Krebs JW, Wheeling JT, Childs JE. Rabies surveillance in the United States during 2002. J Am Vet Assoc 2003;223:1736-1748.
13. Charlton KM. The pathogenesis of rabies and other lyssaviral infections: Recent studies. Curr Top Microbiol Immunol 1994;187:95-119.
14. Childs JE, Colby I, Krebs JW, et al. Surveillance and spatiotemporal associations of rabies in rodents and lagomorphs in the United States, 1985-1994. J Wildl Dis 1997;33:20-27.
15. Messenger SL, Smith JS, Rupprecht CE. Emerging epidemiology of bat-associated cryptic cases of rabies in humans in the United States. Clin Infect Dis 2002;35:738-747.
16. Gibbons RV, Holman RC, Mosberg SR, et al. Knowledge of bat rabies and human exposure among United States cavers. Emerg Infect Dis 2002;8:532-534.
17. Srinivasan A, Burton EC, Kuehnert MJ, et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med 2005;352:1103-1111.
18. Warrell MJ, Warrell DA. Rabies and other lyssavirus diseases. Lancet 2004;363:959-969.
19. Willoughby RE Jr, Tieves KS, Hoffman GM, et al. Survival after treatment of rabies with induction of coma. N Engl J Med 2005;352:2508-2514.
20. Human Rabies Prevention - United States, 1999: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1999;48(RR-1):1-21.
21. Systemic allergic reactions following immunization with human diploid cell rabies vaccine. MMWR 1984;33:185-187.
22. Swanson MC, Rosanoff E, Gurwith M, et al. IgE and IgG antibodies to beta-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine. J Infect Dis 1987;155:909-913.
23. Fishbein DB, Yenne KM, Dreesen DW, et al. Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: A nationwide prospective. Vaccine 1993;11: 1390-1394.
24. Cox JH, Schneider LG. Prophylactic immunization of humans against rabies by intradermal inoculation of human diploid cell culture vaccine. J Clin Microbiol 1976;3:96-101.
25. Kuwert EK, Marcus I, Werner J, et al. Some experiences with human diploid cell strain (HDCS) rabies vaccine in pre- and postexposure vaccinated humans. Develop Biol Standard 1978;40:79-88.
26. Ajjan N, Soulebot JP, Stellmann C, et al. Résultats de la vaccination antirabique preventive par la vaccin inactive concentre souche rabies PM/ W138-1503-3M cultives sur cellules diploides humaines. Develop Biol Standard 1978;40:89-199.
27. Costy-Berger F. Vaccination antirabique préventive par du vaccin prépare sur cellules diploïdes humaines. Develop Biol Standard 1978;40:101-104.
28. Bernard KW, Roberts MA, Sumner J, et al. Human diploid cell rabies vaccine. JAMA 1982;247:1138-1142.
29. Bahmanyar M, Fayaz A, Nour-Salehi S, et al. Successful protection of humans exposed to rabies infection. JAMA 1976;236:2751-2754.
30. Rupprecht CE, Gibbons RV. Prophylaxis against rabies. N Engl J Med 2004;351:2626-2635.
31. Strady A. Antibody persistence following preexposure regimens of cell-culture rabies vaccine: 10 year follow up and proposal for a new booster policy. J Infect Dis 1998;177:1290-1297.
32. Recommendations of the Immunization Practices Advisory Committee (ACIP). Rabies prevention - United States, 1984. MMWR 1984;33:393-402.
33. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon. JAMA 1999;281:1735-1745.
34. Brachman P. Inhalation anthrax. Ann NY Acad Sci 1980;353:83-93.
35. Farrar WE. Anthrax: Virulence and vaccines. Ann Intern Med 1994;121:239-390.
36. Williams RP. Bacillus anthracis and other spore forming bacilli. In Braude AI, Davis LE (eds). Infectious Disease and Medical Microbiology. Philadelphia: WB Saunders, 1986:270-278.
37. Dixon TC, Meselson M, Guillemin J, et al. Anthrax. N Engl J Med 1999;341:815-826.
38. Modlin JF and the Advisory Committee on Immunization Practices. Use of anthrax vaccine in the United States. MMWR 2000;49(RR15):1-20.
39. Tekin A, Bulut N, Unal T. Acute abdomen due to anthrax. Br J Surg 1997;84:813-817.
40. Advisory Committee on Immunization Practices. Adult immunization MMWR 1984;33:33-34.
41. Turnbull PCB. Anthrax vaccines: Past, present and future. Vaccine 1991;9:533-539.
42. Pittman PR, Kim-Ahn G, Pifat DY, et al. Anthrax vaccine: Immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 2002;20:1412-1420.
43. Turnbull PCB, Broster MG, Carman JA, et al. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 1986;52:356-363.
44. Brachman PS, Gold H, Plotkin SA, et al. Field evaluation of a human anthrax vaccine. Am J Publ Health 1962;52:632-645.
45. Chen RT, Rastogi SC, Mullen JR. et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994;12:542-550.
46. Surveillance for adverse effects associated with anthrax vaccination: U.S. Department of Defense, 1998-2000. MMWR 2000;49:341-345.
47. Pittman PR, Gibbs P, Cannon T, et al. Anthrax vaccine. Vaccine 2001;20:972-978.
48. Committee on Health Effects Associated with Exposures during the Gulf War, Institute of Medicine. In: Fulco CE, Liverman CT, Sox HC (eds). Gulf War and Health. Volume I: Depleted uranium, sarin, pyridostigmine bromide, and vaccines. Washington DC: National Academy of Sciences, 2000.
49. Fukuda K, Nisenbaum R, Stewart G, et al. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA 1998;280:981-988.
50. Notice to readers: Use of anthrax vaccine in response to terrorism - Supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR 2002;51:1024-1026.
51. Occupational health guidelines for remediation workers at Bacillus anthracis-contaminated sites in the United States. MMWR 2002;51:786-789.
52. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg 1956;54:28-36.
53. Friedlander AM, Welkos SL, Pitt MLM, et al. Post-exposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993;167:1239-1242.
54. Wassilak SGF, Orenstein WA, Sutter RW. Tetanus toxoid. In Plotkin SA, Orenstein WA (eds). Vaccines. Fourth edition. Philadelphia: WB Saunders, 2004: 745-781.
55. Simonsen O, Kjeldsen K, Heran I. Immunity against tetanus and effect of revaccination 25-30 years after primary vaccination. Lancet 1984;2:1240-1242.
56. Centers for Disease Control and Prevention: Tetanus surveillance - United States, 1995-1997. CDC Surveillance Summaries. MMWR 1998;47(SS-2):1-13.
57. Centers for Disease Control and Prevention: Tetanus surveillance - United States, 1982-1984. CDC Surveillance Summaries. MMWR 1985;34:602-611.
58. Centers for Disease Control and Prevention: Tetanus surveillance - United States, 1987-1988. CDC Surveillance Summaries. MMWR 1990;39:37-34.
59. Schwartz E, Rodeisperger E. Skin and soft tissue infections. In Schillinger D, Harwood-Nuss A (eds). Infections in Emergency Medicine (volume 2). New York: Churchill Livingstone, 1990:63-113.
60. Bleck TP, Brauner JS. Tetanus. In Scheld WM, Whitely RI, Durack DT (eds). Infections of the Central Nervous System. Second edition. Philadelphia: Lippincott-Raven, 1997:629-653.
61. Veronesi R, Focaccia R. The clinical picture. In Veronesi R (ed). Tetanus: Important New Concepts. Amsterdam: Excerpta Medica, 1981:183-206.
62. Trujillo MH, Castillo A, Espana J, et al. Impact of intensive care management of the prognosis of tetanus. Chest 1987;92:63-65.
63. Wright DK, Lalloo UG, Nayiager S, et al. Autonomic nervous system dysfunction in severe tetanus: Current perspectives. Crit Care Med 1989; 17:371-375.
64. Domenighetti GM, Savary G, Stricker H. Hyperadrenergic syndrome in severe tetanus: Extreme rise in catecholamines responsive to labetolol. Br Med J 1984;288:1483-1484.
65. Edlich RF, Silloway KA, Haines PC, et al. Tetanus. Comprehen Ther 1986;12:12-21.
66. Jagoda A, Riggio S, Burgieres T. Cephalic tetanus: A case report and review of the literature. Am J Emerg Med 1988;6:128-130.
67. Centers for Disease Control. Diphtheria, tetanus, and pertussis: Recommendations for vaccine use and other preventive measures. MMWR 1991;40:1-28.
68. Prevots DR. Neonatal tetanus. Bull WHO 1998;76: 135-136.
69. Crone NE, Reeder AT. Severe tetanus in immunized patients with high anti-tetanus titers. Neurology 1992;42:761-764.
70. Litovitz TL, Klein-Schwartz W, Dyer KS, et al. Annual report of the American Association of Poison Control Centers Toxic Surveillance System. Am J Emerg Med 1998;16:443-497.
71. Crossley K, Irvine P, Warren JB, et al. Tetanus and diphtheria immunity in urban Minnesota adults. JAMA 1979;242:2298-2300.
72. Kolbin BA, Townsend TR. Immunity to diphtheria and tetanus in inner-city women of childbearing age. Am J Publ Health 1989;79:1297-1298.
73. Weiss BP, Strassburg MA, Feeley JC. Tetanus and diphtheria immunity in an elderly population in Los Angeles County. Am J Publ Health 1983;73:802-804.
74. Levine L, McComb JA, Dwyer RC, et al. Active-passive tetanus immunization: Choice of toxoid, dose of tetanus immune globulin and timing of injections. N Engl J Med 1966;274:186-190.
75. Stiehm ER. Standard and special human immune serum globulin as therapeutic agents. Pediatrics 1979;63:301-319.
76. Myers MG. Primary immunization with tetanus and diphtheria toxoids. JAMA 1982;248:2478-2480.
77. Centers for Disease Control and Prevention. Recommendations on immunization from the ACIP and the American Academy of Family Physicians. MMWR 2002;51(RR-2):1-35.
78. Gergen PJ, McQuillan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 1995;332:761-766.
79. Talan DA, Abrahamian FM, Morgan GJ, et al. Tetanus immunity and physician compliance with tetanus prophylaxis practices among emergency department patients presenting with wounds. Ann Emerg Med 2004;43:305-314.
80. Dietz V, Galazka A, Loon F, et al. Factors affecting the immunogenicity and potency of tetanus toxoid: Implications for the elimination of neonatal and non-neonatal tetanus as public health problems. Bull WHO 1997;75:81-93.
81. Hsu SS, Groleau G. Tetanus in the emergency department: A current review. J Emerg Med 2002;20: 357-365.
82. Morris DH, Bullock FD. The importance of the spleen in resistance to infection. Ann Surg 1919;70: 513-521.
83. King H, Schumacker HB, Splenic studies: Susceptibility to infection after splenectomy performed in infancy. Ann Surg 1952;136:239-242.
84. Diamond LK. Splenectomy in childhood and the hazard of overwhelming infection. Pediatrics 1969; 443:886-889.
85. Bichner ER. Splenic function: Normal, too much and too little. Am J Med 1979;66:311-320.
86. Kruetzmann S, Rosado MM, Weber H, et al. Human immune globulin IgM memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 2003;197:939-945.
87. Brukels MA, Zandvoort A, van den Dobblesteen GPM, et al. Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharides. Infect Immun 2001; 69:7583-7587.
88. Najjar VA, Nishioka K. Tuftsin. A natural phagocytosis stimulating peptide. Nature 1970;228:672-673.
89. Constantopoulos A, Najjar VA, Wish JB, et al. Defective phagocytosis due to tuftsin deficiency in splenectomized subjects. Am J Dis Child 1973;125: 663-665.
90. Szendroi T, Miko I, Hajdu Z, et al. Splenic autotransplantation after abdominal trauma in childhood. Acta Chir Hung 1997;36:349-351.
91. Sumaraju V, Smith LG, Smith S. Infectious implications in asplenic hosts. Infect Dis Clin North Am 2001;15:551-565.
92. Brigden ML, Pattullo AL. Prevention and management of overwhelming postsplenectomy infection - An update. Crit Care Med 1999;27:836-842.
93. Lortan JE. Management of asplenic patients. Br J Haematol 1993;84:566-569.
94. Holdsworth RJ, Irvin AD, Cushierr A. Postsplenectomy sepsis and mortality rate: Actual versus perceived risk. Br J Surg 1991;78:1031-1038.
95. Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med 1995;122:187-188.
96. Singer DB. Postsplenectomy sepsis. In Rosenberg HS, Bolande RP (eds). Perspectives in Pediatric Pathology (volume 1). Chicago: Year Book Medical Publishers, 1973:285-311.
97. Weintraub LR. Splenectomy: Who, when, and why? Hosp Pract 1994;29:27-34.
98. Shaw JHF, Print CG. Postsplenectomy sepsis. Br J Surg 1989;76:1074-1081.
99. Moore GE, Stevens RE, Moore EE, et al. Failure of splenic implants to protect against fatal postsplenectomy infection. Am J Surg 1983;146:413-414.
100. Konradsen HB, Henrichsen J. Pneumococcal infections in splenectomized children are preventable. Acta Paediatr Scand 1991;80:423-427.
101. Schwartz PE, Sterioff S, Much P, et al. Postsplenectomy sepsis and mortality in adults. JAMA 1982; 248:2274-2283.
102. Walker W. Splenectomy in childhood: A review in England and Wales. Br J Surg 1976;63:36-43.
103. De Cataldo A, Puleo S, Li Destri G, et al. Splenic trauma and overwhelming postsplenectomy infection. Br J Surg 1987;74:343-345.
104. Cullingham GL, Watkins DN, Watts AD, et al. Severe late postsplenectomy infection. Br J Surg 1991; 78:716-721.
105. Torres J, Bisno AL. Hyposplenism and pneumococcemia: Visualization of Diplococcus pneumoniae in peripheral blood smear. Am J Med 1973;555: 851-855.
106. Rosner F, Zarrabi MH, Benach JL, et al. Babesiosis in splenectomized adults: Review of 22 reported cases. Am J Med 1984;76:696-701.
107. Brigden ML. Overwhelming postsplenectomy infection - Still a problem. West J Med 1992;157:440-443.
108. Green JB, Shackford SR, Sise MJ, et al. Late septic complications in adults following splenectomy for trauma: A prospective analysis in 144 patients. J Trauma 1986;26:999-1004.
109. Lynch AM, Kapila R. Overwhelming postsplenectomy infection. Infect Dis Clin North Am 1996;4: 693-707.
110. Poland GA. The prevention of pneumococcal disease by vaccines: Promises and challenges. Infect Dis Clin North Am 2001;15:97-122.
111. Breiman RF, Butler JC, Tenover FC, et al. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-1840.
112. Musher DM, Groover JF, Rowland JM, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: Prevalence, persistence, and response to revaccination. Clin Infect Dis 1993;17:66-79.
113. Robbins JB. Schneerson R. Polysaccharide-protein conjugates: A new generation of vaccines. J Infect Dis 1990;161:821-832.
114. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients: Results of a Veterans Administration cooperative study. N Engl J Med 1986;315:1318-1327.
115. Forrester HL, Jahnigen DW, La Force FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987;83:425-436.
116. Ortqvisdt A, Hedlund J, Burman LA, et al. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in the prevention of pneumonia in middle-aged and elderly people. Lancet 1998;351:399-410.
117. Lehmann D, Marshall TF, Riley ID, et al. Effect of pneumococcal vaccine on morbidity from acute lower respiration tract infections in Papua New Guinea children. Ann Trop Paediatr 1991;11:247-255.
118. Macleod CM, Hodges RG, Heidelberger M, et al. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945;82:445-460.
119. Farr BM, Johnston L, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk: Results of a matched case-control study. Arch Intern Med 1995;155:2336-2348.
120. Fedson DS. Pneumococcal vaccination for older adults: The first 20 years. Drugs Aging 1999;15: 21-40.
121. Kayhty H, Ahman H, Ronnberg PR, et al. Pneumococcal polysaccharide protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 1995;172:1273-1281.
122. Anderson EL, Kennedy DJ, Geldmacher KM, et al. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996;128:649-660.
123. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults: A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-2682.
124. Lawrence EM, Edwards KM, Shiffman C, et al. Pneumococcal vaccine in normal children. Am J Dis Child 1983;137:846-855.
125. Mufson MA, Hughey DF, Turner CE, et al. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine 1991;9: 403-412.
126. Black S, Shinefiled H, Fireman B, et al. Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis 2000;19:187-200.
127. Broome CV. Epidemiology of Haemophilus influenzae type b infections in the United States. Pediatr Infect Dis 1987;6:779-782.
128. Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children - United States 1998-2000. MMWR 2002;51: 234-237.
129. Cimaz R, Mensi C, D'Angelo E, et al. Safety and immunogenicity of a conjugate vaccine against Haemophilus influenzae type b in splenectomized and non-splenectomized patients with Cooley anemia. J Infect Dis 2001;183:1819-1821.
130. Jakacki R, Luery N, McVerry P, et al. Haemophilus influenzae-diphtheria protein conjugate immunization in splenectomized patients with Hodgkin's disease. Ann Intern Med 1990;112:143-144.
131. Peltola H. Prevention of Haemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984;310:1561-1566.
132. Kaplan SL. Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children with sickle cell hemoglobinopathy or malignancies. J Pediatr 1992;120: 367-370.
133. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999;180: 1894-1901.
134. Zollinger W, Boslego J, Frasch C, et al. Safety of vaccines containing meningococcal group b polysaccharide. Lancet 1984;2:166-175.
135. Finne J, Bitter-Suermann D, Goridis C, et al. An IgG monoclonal antibody to group b meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987;138:4402-4407.
136. Mandrell R, Zollinger W. Measurement of antibodies to meningococcal serogroup b polysaccharide: Low avidity binding and equilibrium binding constants. J Immunol 1982;129:2172-2177.
137. Hankins WA. Clinical and serological evaluation of a meningococcal polysaccharide vaccine, groups A, C, Y, and W-135. Proc Soc Exp Biol Med 1982;169: 54-57.
138. Lepow ML. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J Infect Dis 1986;154: 1033-1036.
139. Abildgaard N, Nielsen JL. Pneumococcal septicemia and meningitis in vaccinated splenectomized adult patients. Scand J Infect Dis 1994;26:615-617.
140. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46:12-15.
141. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-1460.
142. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations. JAMA 1993;270: 1826-1831.
143. Barbour ML. Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerg Infect Dis 1996; 2:176-182.
144. Hazelwood M, Nusrat R, Kumarmatne DS, et al. The acquisition of anti-pneumococcal capsular polysaccharide, Haemophilus influenzae type b and tetanus toxoid antibodies with age in the UK. Clin Exp Immunol 1993;93:157-164.
145. Konradsen HB, Rasmussen C, Ejstrud P, et al. Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status. Epidemiol Infect 1997;119:167-174.
146. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR 1993;42(RR4):1-18.
147. Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49 (RR7):1-3.
148. Giebink GS, Foker JE, Kim Y, et al. Serum antibody and opsonic responses to vaccination with pneumococcal capsular polysaccharide in normal and splenectomized children. J Infect Dis 1980;141: 404-412.
149. Barringer M, Meredith W, Starch M, et al. Effect of anesthesia and splenectomy on antibody response to pneumococcal polysaccharide immunization. Am Surg 1982;48:628-633.
150. Caplan ES, Boltansky H, Synder MJ, et al. Response of traumatized splenectomized patients to immediate vaccination with polyvalent pneumococcal vaccine. J Trauma 1983;23:801-805.
151. Pedersen FK, Nielsen JL, Andersen V, et al. Proposal for the prevention of fulminant infection after splenectomy. Ugeskr Laeger 1992;144:1453-1456.
152. Shatz DV, Schinsky MF, Pais LB, et al. Immune responses of splenectomized trauma patients to the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after splenectomy. J Trauma 1998;44:760-766.
153. Romero-Steiner S, Libutti D, Pais LB. et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997; 4:415-422.
154. Vernacchio L, Romero-Steiner S, Martinez JE, et al. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease. J Infect Dis 2000;181:1162-1166.
155. Shatz DV, Romero-Steiner S, Ellie C, et al. Antibody responses at 14 and 28 days postsplenectomy in trauma patients receiving the 23-valent pneumococcal vaccine. J Trauma 2002;52:194-200.
156. Mufson MA, Krause HE, Schiffman C. Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine. Proc Soc Exp Biol Med 1983;173:270-275.
157. Giebink GS, Le CT, Schiffman G. Decline of serum antibody in splenectomized children after vaccination with pneumococcal capsular polysaccharides. J Pediatr 1984;105:576-581.
158. American Academy of Pediatrics, Committee on Infectious Disease. Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000;106:362-366.